Year-end Sale % OFF 
Abstract
Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model.
Highlights
Reviewed by: Yona Levites, University of Florida, United States Merina Varghese, Icahn School of Medicine at Mount Sinai, United States
Treatment started at the age of 2 months and outcome measurements were tested at the ages of 4 to 8 months
Given the above-described previous reports by this team, it is surprising that the current study (Lin et al, 2020) is based upon results from an experiment performed using 22 female JNPL3 mice at the advanced age of 10–11 months, much older than previously used and at which according to the authors—the female mice suffer from severe motor disability
Summary
Reviewed by: Yona Levites, University of Florida, United States Merina Varghese, Icahn School of Medicine at Mount Sinai, United States. In a recent paper in Frontiers in Aging Neuroscience (Lin et al, 2020), the authors purported to examine treatment efficacy of Programmed cell death protein (PD)-1 antibody blockade in a tauopathy mouse model in a weekly administration regimen, which the authors refer to as “chronic,” supposedly based on the studies by Schwartz’s team (Baruch et al, 2016; Rosenzweig et al, 2019).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
